BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 23785172)

  • 1. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis.
    Heinzel A; Müller D; Langen KJ; Blaum M; Verburg FA; Mottaghy FM; Galldiks N
    J Nucl Med; 2013 Aug; 54(8):1217-22. PubMed ID: 23785172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
    Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
    J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
    Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas.
    Heinzel A; Stock S; Langen KJ; Müller D
    Eur J Nucl Med Mol Imaging; 2012 Jul; 39(7):1089-96. PubMed ID: 22419257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis.
    Heinzel A; Müller D; Yekta-Michael SS; Ceccon G; Langen KJ; Mottaghy FM; Wiesmann M; Kocher M; Hattingen E; Galldiks N
    Neuro Oncol; 2017 Sep; 19(9):1271-1278. PubMed ID: 28204572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
    Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
    World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma.
    Galldiks N; Stoffels G; Ruge MI; Rapp M; Sabel M; Reifenberger G; Erdem Z; Shah NJ; Fink GR; Coenen HH; Langen KJ
    J Nucl Med; 2013 Dec; 54(12):2046-54. PubMed ID: 24159047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study.
    Bashir A; Brennum J; Broholm H; Law I
    J Neurosurg; 2018 Apr; 130(2):451-464. PubMed ID: 29624154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost Effectiveness of
    Rosen J; Ceccon G; Bauer EK; Werner JM; Tscherpel C; Dunkl V; Rapp M; Sabel M; Herrlinger U; Heinzel A; Schäfer N; Ruge M; Goldbrunner R; Stoffels G; Kabbasch C; Fink GR; Langen KJ; Galldiks N
    J Nucl Med; 2022 Nov; 63(11):1677-1682. PubMed ID: 35422443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI and
    Rosen J; Werner JM; Ceccon GS; Rosen EK; Wollring MM; Stetter I; Lohmann P; Mottaghy FM; Fink GR; Langen KJ; Galldiks N
    J Nucl Med; 2024 Jun; 65(6):838-844. PubMed ID: 38664020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of O-(2-
    Verger A; Filss CP; Lohmann P; Stoffels G; Sabel M; Wittsack HJ; Kops ER; Galldiks N; Fink GR; Shah NJ; Langen KJ
    World Neurosurg; 2018 May; 113():e727-e737. PubMed ID: 29510293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.
    Galldiks N; Stoffels G; Filss C; Rapp M; Blau T; Tscherpel C; Ceccon G; Dunkl V; Weinzierl M; Stoffel M; Sabel M; Fink GR; Shah NJ; Langen KJ
    Neuro Oncol; 2015 Sep; 17(9):1293-300. PubMed ID: 26008606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors.
    Filss CP; Galldiks N; Stoffels G; Sabel M; Wittsack HJ; Turowski B; Antoch G; Zhang K; Fink GR; Coenen HH; Shah NJ; Herzog H; Langen KJ
    J Nucl Med; 2014 Apr; 55(4):540-5. PubMed ID: 24578243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential for differentiation of glioma recurrence from radionecrosis using integrated
    Sogani SK; Jena A; Taneja S; Gambhir A; Mishra AK; D'Souza MM; Verma SM; Hazari PP; Negi P; Jadhav GK
    Neurol India; 2017; 65(2):293-301. PubMed ID: 28290392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of
    Verger A; Filss CP; Lohmann P; Stoffels G; Sabel M; Wittsack HJ; Kops ER; Galldiks N; Fink GR; Shah NJ; Langen KJ
    Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2257-2265. PubMed ID: 28831534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of amino acid PET-guided surgery for supratentorial high-grade gliomas.
    Heinzel A; Stock S; Langen KJ; Müller D
    J Nucl Med; 2012 Apr; 53(4):552-8. PubMed ID: 22419752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spatial Relationship of Glioma Volume Derived from
    Mauler J; Maudsley AA; Langen KJ; Nikoubashman O; Stoffels G; Sheriff S; Lohmann P; Filss C; Galldiks N; Kops ER; Shah NJ
    J Nucl Med; 2018 Apr; 59(4):603-609. PubMed ID: 28848036
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Fleischmann DF; Unterrainer M; Bartenstein P; Belka C; Albert NL; Niyazi M
    J Neurooncol; 2017 Apr; 132(2):277-286. PubMed ID: 28102485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
    Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense?
    Unterrainer M; Schweisthal F; Suchorska B; Wenter V; Schmid-Tannwald C; Fendler WP; Schüller U; Bartenstein P; Tonn JC; Albert NL
    J Nucl Med; 2016 Aug; 57(8):1177-82. PubMed ID: 27033893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.